These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34835296)

  • 1. SARS-CoV-2 Spike Protein-Induced Interleukin 6 Signaling Is Blocked by a Plant-Produced Anti-Interleukin 6 Receptor Monoclonal Antibody.
    Jugler C; Sun H; Chen Q
    Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Hybrid Soluble gp130/Spike-Nanobody Fusion Protein Simultaneously Blocks Interleukin-6
    Ettich J; Werner J; Weitz HT; Mueller E; Schwarzer R; Lang PA; Scheller J; Moll JM
    J Virol; 2022 Feb; 96(4):e0162221. PubMed ID: 34935434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
    Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
    Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential for a Plant-Made SARS-CoV-2 Neutralizing Monoclonal Antibody as a Synergetic Cocktail Component.
    Jugler C; Sun H; Grill F; Kibler K; Esqueda A; Lai H; Li Y; Lake D; Chen Q
    Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibody therapy in COVID-19.
    Conti P; Pregliasco FE; Calvisi V; Caraffa Al; Gallenga CE; Kritas SK; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(2):423-427. PubMed ID: 33904269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal Antibodies B38 and H4 Produced in
    Shanmugaraj B; Rattanapisit K; Manopwisedjaroen S; Thitithanyanont A; Phoolcharoen W
    Front Plant Sci; 2020; 11():589995. PubMed ID: 33329653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in Nicotiana benthamiana.
    Rattanapisit K; Shanmugaraj B; Manopwisedjaroen S; Purwono PB; Siriwattananon K; Khorattanakulchai N; Hanittinan O; Boonyayothin W; Thitithanyanont A; Smith DR; Phoolcharoen W
    Sci Rep; 2020 Oct; 10(1):17698. PubMed ID: 33077899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 spike protein promotes IL-6 trans-signaling by activation of angiotensin II receptor signaling in epithelial cells.
    Patra T; Meyer K; Geerling L; Isbell TS; Hoft DF; Brien J; Pinto AK; Ray RB; Ray R
    PLoS Pathog; 2020 Dec; 16(12):e1009128. PubMed ID: 33284859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.
    Conti P; Caraffa A; Tetè G; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G
    J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1629-1632. PubMed ID: 32945158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plant-produced SARS-CoV-2 receptor binding domain (RBD) variants showed differential binding efficiency with anti-spike specific monoclonal antibodies.
    Rattanapisit K; Bulaon CJI; Khorattanakulchai N; Shanmugaraj B; Wangkanont K; Phoolcharoen W
    PLoS One; 2021; 16(8):e0253574. PubMed ID: 34379620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome-An Observational Pilot Study.
    Notz Q; Schmalzing M; Wedekink F; Schlesinger T; Gernert M; Herrmann J; Sorger L; Weismann D; Schmid B; Sitter M; Schlegel N; Kranke P; Wischhusen J; Meybohm P; Lotz C
    Front Immunol; 2020; 11():581338. PubMed ID: 33123167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interplay of Antibody and Cytokine Production Reveals CXCL13 as a Potential Novel Biomarker of Lethal SARS-CoV-2 Infection.
    Horspool AM; Kieffer T; Russ BP; DeJong MA; Wolf MA; Karakiozis JM; Hickey BJ; Fagone P; Tacker DH; Bevere JR; Martinez I; Barbier M; Perrotta PL; Damron FH
    mSphere; 2021 Jan; 6(1):. PubMed ID: 33472985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic targeting of interleukin-6 for the treatment of COVID-19.
    Wang Y; Liu C; Miao X; Kong D; Zhao Y; Gong W; Ding X
    Eur Cytokine Netw; 2020 Dec; ():. PubMed ID: 33270024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters.
    Su W; Sia SF; Schmitz AJ; Bricker TL; Starr TN; Greaney AJ; Turner JS; Mohammed BM; Liu Z; Choy KT; Darling TL; Joshi A; Cheng KM; Wong AYL; Harastani HH; Nicholls JM; Whelan SPJ; Bloom JD; Yen HL; Ellebedy AH; Boon ACM
    mBio; 2021 Oct; 12(5):e0239521. PubMed ID: 34517754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 Spike Protein Induces Paracrine Senescence and Leukocyte Adhesion in Endothelial Cells.
    Meyer K; Patra T; Vijayamahantesh ; Ray R
    J Virol; 2021 Aug; 95(17):e0079421. PubMed ID: 34160250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine Signature Induced by SARS-CoV-2 Spike Protein in a Mouse Model.
    Gu T; Zhao S; Jin G; Song M; Zhi Y; Zhao R; Ma F; Zheng Y; Wang K; Liu H; Xin M; Han W; Li X; Dong CD; Liu K; Dong Z
    Front Immunol; 2020; 11():621441. PubMed ID: 33584719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab.
    Agresti N; Lalezari JP; Amodeo PP; Mody K; Mosher SF; Seethamraju H; Kelly SA; Pourhassan NZ; Sudduth CD; Bovinet C; ElSharkawi AE; Patterson BK; Stephen R; Sacha JB; Wu HL; Gross SA; Dhody K
    J Transl Autoimmun; 2021; 4():100083. PubMed ID: 33521616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy.
    Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Ronconi G
    J Biol Regul Homeost Agents; 2020; 34(6):1971-1975. PubMed ID: 33016027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tocilizumab as a Treatment for 'Cytokine Storm Syndrome' in COVID-19: A Case Report.
    Syam AF; Pitoyo CW; Suhendro S; Zulkarnain B; Indrasari ND; Aditianingsih D; Irawan C; Susilo A; Rumende CM; Wijaya IP; Ibrahim F; Rasmin M; Alwi I; Makmun D
    Acta Med Indones; 2021 Apr; 53(2):194-201. PubMed ID: 34251348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo efficacy of anti-chikungunya virus monoclonal antibodies produced in wild-type and glycoengineered Nicotiana benthamiana plants.
    Hurtado J; Acharya D; Lai H; Sun H; Kallolimath S; Steinkellner H; Bai F; Chen Q
    Plant Biotechnol J; 2020 Jan; 18(1):266-273. PubMed ID: 31207008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.